Skip to content

Advertisement

  • Poster presentation
  • Open Access

Analysis of continuous biochemical parameters in long-term trials of chronic disease where outcomes could be affected by further intervention

  • Natalie Ives1,
  • Samir Mehta1,
  • Elizabeth Brettell1,
  • Marie Valente1 and
  • Sunil Bhandari2
Trials201516(Suppl 2):P62

https://doi.org/10.1186/1745-6215-16-S2-P62

Published: 16 November 2015

Keywords

Chronic Kidney DiseaseAngiotensinRenal DiseaseGlomerular Filtration RateGlomerular Filtration

Background

Chronic kidney disease (CKD) affects 1 in 10 adults in the UK, and is an increasing burden on the NHS - dialysis costs ~£30,000/year. Key clinical outcomes in CKD are need for dialysis or transplantation and survival. However, designing trials with these endpoints requires large patient numbers. To reduce sample size requirements, trials have used measures of renal function (e.g. serum creatinine, glomerular filtration rate), which correlate with longer-term clinical outcomes. However, there are interpretation issues for these parameters if the rate of dialysis or transplant is affected by treatment group, as these interventions impact on renal function.

Methods

We plan to undertake a review of studies in stage 4/5 renal disease to assess analysis methods used. Have trials excluded patients from the analysis when they start dialysis or have a transplant, or if they are included, what methods have been used to account for this or potential data missing not at random. Possible options include last observation carried forward, flat value or multiple imputation. Based on this review, we plan to assess the different analysis methods in terms how results may vary and which provides the most robust result.

Results

The results will inform the statistical analysis plan for the STOP-ACEi trial (funded by NIHR EME) assessing withdrawal of ACE-inhibitors and Angiotensin Receptor Blockers in patients with advanced CKD.

Conclusions

Although this example relates to renal disease, there are other areas where continuous outcomes are used in trials, where other factors may influence or impact on this outcome.

Authors’ Affiliations

(1)
University of Birmingham, Birmingham, UK
(2)
Hull and East Yorkshire Hospitals NHS Trust, Hull, UK

Copyright

© Ives et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Please note that comments may be removed without notice if they are flagged by another user or do not comply with our community guidelines.

Advertisement